Intel stock spikes after report of possible US government stake
SAN FRANCISCO—On February 11, 2025, Bryson Anna, the Chief Financial Officer of Doximity , Inc. (NYSE:DOCS), executed a series of stock transactions involving the company’s Class A Common Stock. The transactions were disclosed in a recent SEC Form 4 filing. The stock has shown remarkable momentum, with a 159% return over the past year and a recent surge of 29% in the past week, according to InvestingPro data.
Anna sold a total of 94,000 shares of Doximity stock, amounting to approximately $7.22 million. The sales were carried out at prices ranging from $74.9981 to $79.5821 per share. These sales were part of a pre-arranged trading plan under Rule 10b5-1, which allows insiders to set up a predetermined schedule for selling stocks to avoid potential accusations of insider trading.
In addition to the sales, Anna also exercised stock options to acquire 95,000 shares of Class B Common Stock, which were converted into Class A Common Stock. Following these transactions, Anna holds 329,386 shares in the company.
Doximity, a digital platform for medical professionals, continues to maintain its headquarters in San Francisco, California. According to InvestingPro’s comprehensive analysis, which includes over 30 key metrics and financial indicators, the company currently trades above its Fair Value, with 12 analysts recently revising their earnings expectations upward for the upcoming period.
In other recent news, Doximity Inc has been the subject of multiple analyst updates following its impressive third-quarter results. Jefferies analyst Glen Santangelo increased the price target for Doximity to $88 from $64, citing the company’s significant growth rate and high EBITDA margin. Likewise, Mizuho (NYSE:MFG) Securities analyst Steven Valiquette raised the price target to $65 from $55, following Doximity’s revenue of $168 million, a 25% year-over-year increase, and an EBITDA of $102 million, showing a 39% growth.
Piper Sandler analyst Sean Wieland upgraded Doximity’s stock rating from Neutral to Overweight and raised the price target to $78 from $31, based on the company’s accelerating revenue growth. KeyBanc Capital Markets maintained its $65 price target on Doximity, following the company’s top- and bottom-line growth, with revenues increasing by 25% year-over-year. Lastly, Needham maintained a Buy rating on Doximity and increased its price target to $82 from $65, following an exceptional third quarter that saw an unprecedented adjusted EBITDA margin surpassing 60%.
These recent developments reflect the analysts’ confidence in Doximity’s growth trajectory and its ability to sustain high profitability. The revised estimates and ratings underscore the company’s successful execution and promising outlook in its sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.